725 related articles for article (PubMed ID: 16507759)
1. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease.
El-Agnaf OM; Salem SA; Paleologou KE; Curran MD; Gibson MJ; Court JA; Schlossmacher MG; Allsop D
FASEB J; 2006 Mar; 20(3):419-25. PubMed ID: 16507759
[TBL] [Abstract][Full Text] [Related]
2. Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss?
Ohrfelt A; Grognet P; Andreasen N; Wallin A; Vanmechelen E; Blennow K; Zetterberg H
Neurosci Lett; 2009 Feb; 450(3):332-5. PubMed ID: 19022350
[TBL] [Abstract][Full Text] [Related]
3. Phosphorylated α-synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson's disease.
Foulds PG; Mitchell JD; Parker A; Turner R; Green G; Diggle P; Hasegawa M; Taylor M; Mann D; Allsop D
FASEB J; 2011 Dec; 25(12):4127-37. PubMed ID: 21865317
[TBL] [Abstract][Full Text] [Related]
4. Plasma alpha-synuclein in patients with Parkinson's disease with and without treatment.
Duran R; Barrero FJ; Morales B; Luna JD; Ramirez M; Vives F
Mov Disord; 2010 Mar; 25(4):489-93. PubMed ID: 20063406
[TBL] [Abstract][Full Text] [Related]
5. Detection of α-synuclein oligomers in red blood cells as a potential biomarker of Parkinson's disease.
Wang X; Yu S; Li F; Feng T
Neurosci Lett; 2015 Jul; 599():115-9. PubMed ID: 25998655
[TBL] [Abstract][Full Text] [Related]
6. Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias.
Parnetti L; Chiasserini D; Bellomo G; Giannandrea D; De Carlo C; Qureshi MM; Ardah MT; Varghese S; Bonanni L; Borroni B; Tambasco N; Eusebi P; Rossi A; Onofrj M; Padovani A; Calabresi P; El-Agnaf O
Mov Disord; 2011 Jul; 26(8):1428-35. PubMed ID: 21469206
[TBL] [Abstract][Full Text] [Related]
7. Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease.
Tokuda T; Salem SA; Allsop D; Mizuno T; Nakagawa M; Qureshi MM; Locascio JJ; Schlossmacher MG; El-Agnaf OM
Biochem Biophys Res Commun; 2006 Oct; 349(1):162-6. PubMed ID: 16930553
[TBL] [Abstract][Full Text] [Related]
8. Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease.
Tokuda T; Qureshi MM; Ardah MT; Varghese S; Shehab SA; Kasai T; Ishigami N; Tamaoka A; Nakagawa M; El-Agnaf OM
Neurology; 2010 Nov; 75(20):1766-72. PubMed ID: 20962290
[TBL] [Abstract][Full Text] [Related]
9. Naturally occurring α-synuclein autoantibody levels are lower in patients with Parkinson disease.
Besong-Agbo D; Wolf E; Jessen F; Oechsner M; Hametner E; Poewe W; Reindl M; Oertel WH; Noelker C; Bacher M; Dodel R
Neurology; 2013 Jan; 80(2):169-75. PubMed ID: 23255825
[TBL] [Abstract][Full Text] [Related]
10. Quantification of α-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies.
Mollenhauer B; El-Agnaf OM; Marcus K; Trenkwalder C; Schlossmacher MG
Biomark Med; 2010 Oct; 4(5):683-99. PubMed ID: 20945981
[TBL] [Abstract][Full Text] [Related]
11. Sensitive and specific detection of α-synuclein in human plasma.
Tinsley RB; Kotschet K; Modesto D; Ng H; Wang Y; Nagley P; Shaw G; Horne MK
J Neurosci Res; 2010 Sep; 88(12):2693-700. PubMed ID: 20648655
[TBL] [Abstract][Full Text] [Related]
12. Sensitive fluorescence polarization technique for rapid screening of alpha-synuclein oligomerization/fibrillization inhibitors.
Luk KC; Hyde EG; Trojanowski JQ; Lee VM
Biochemistry; 2007 Nov; 46(44):12522-9. PubMed ID: 17927212
[TBL] [Abstract][Full Text] [Related]
13. Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease.
Majbour NK; Vaikath NN; van Dijk KD; Ardah MT; Varghese S; Vesterager LB; Montezinho LP; Poole S; Safieh-Garabedian B; Tokuda T; Teunissen CE; Berendse HW; van de Berg WD; El-Agnaf OM
Mol Neurodegener; 2016 Jan; 11():7. PubMed ID: 26782965
[TBL] [Abstract][Full Text] [Related]
14. CSF α-synuclein does not differentiate between parkinsonian disorders.
Aerts MB; Esselink RA; Abdo WF; Bloem BR; Verbeek MM
Neurobiol Aging; 2012 Feb; 33(2):430.e1-3. PubMed ID: 21236518
[TBL] [Abstract][Full Text] [Related]
15. Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma.
El-Agnaf OM; Salem SA; Paleologou KE; Cooper LJ; Fullwood NJ; Gibson MJ; Curran MD; Court JA; Mann DM; Ikeda S; Cookson MR; Hardy J; Allsop D
FASEB J; 2003 Oct; 17(13):1945-7. PubMed ID: 14519670
[TBL] [Abstract][Full Text] [Related]
16. Oligomeric α-synuclein and β-amyloid variants as potential biomarkers for Parkinson's and Alzheimer's diseases.
Williams SM; Schulz P; Sierks MR
Eur J Neurosci; 2016 Jan; 43(1):3-16. PubMed ID: 26332448
[TBL] [Abstract][Full Text] [Related]
17. Determination of alpha-synuclein concentration in human plasma using ELISA.
Fjorback AW; Varming K; Jensen PH
Scand J Clin Lab Invest; 2007; 67(4):431-5. PubMed ID: 17558898
[TBL] [Abstract][Full Text] [Related]
18. Plasma alpha-synuclein is decreased in subjects with Parkinson's disease.
Li QX; Mok SS; Laughton KM; McLean CA; Cappai R; Masters CL; Culvenor JG; Horne MK
Exp Neurol; 2007 Apr; 204(2):583-8. PubMed ID: 17258710
[TBL] [Abstract][Full Text] [Related]
19. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
Lo Bianco C; Ridet JL; Schneider BL; Deglon N; Aebischer P
Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10813-8. PubMed ID: 12122208
[TBL] [Abstract][Full Text] [Related]
20. [Alpha-Synuclein in blood and cerebrospinal fluid of patients with alpha-synucleinopathy].
Ono K; Yamada M
Rinsho Byori; 2014 Mar; 62(3):241-5. PubMed ID: 24800499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
